Both Pgp and MRP1 Activities Using Calcein-AM Contribute to Drug Resistance in AML View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

1999

AUTHORS

Ollivier Legrand , Ghislaine Simonin , Jean-Yves Perrot , Robert Zittoun , Jean-Pierre Marie

ABSTRACT

Thirteen cell lines with different levels of Pgp and MRP1 expression were used to assess the ability of calcein-AM uptake and calcein efflux to measure Pgp and MRP1 functions, respectively. There was a good correlation between MRP1 expression and the modulatory effect of probenecid (a specific modulator of MRP1) on the calcein efflux (r=0.91, p=0.0003) and between Pgp expression and the modulatory effect of CsA on calcein-AM uptake (r=0.96, p<0.0001). On light of the high correlations for both proteins, we tested calcein-AM uptake and efflux in fresh myeloid leukemic cells. In 53 AML patients, there was also a good correlation between MRP1 expression (measured by RT/PCR and by MRPm6 expression by flow cytometry) and the modulatory effect of probenecid on the calcein fluorescence (r=0.92, p<0.0001) and between Pgp expression as measured by UIC2 antibody binding on flow cytometry and the modulatory effect of CsA on calcein-AM uptake (r=0.83, p<0.0001). Pgp activity was higher in CD34+ leukemia than in CD34- leukemia (2.26±1.50 vs 1.46±1.21 respectively, p=0.003) and MRP1 activity was higher in CD34- leukemia than in CD34+ leukemia (1.77±0.40 vs 1.4±0.29 respectively, p=0.004). Pgp expression and activity (p=0.004 and p=0.01, respectively), MRP1 activity (p=0.03) but not MRP1 expression were prognostic factors for achievement of CR. The effect of probenecid and CsA together were higher than the effect of either probenecid or CsA alone on calcein-AM uptake. These results suggest that functional testing (with calcein-AM±modulators) for the presence of both MRP1 and Pgp activities is of prognostic value and that MRP1 contributes to drug resistance in AML. More... »

PAGES

161-175

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4615-4811-9_18

DOI

http://dx.doi.org/10.1007/978-1-4615-4811-9_18

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034938308

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10500791


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ATP Binding Cassette Transporter, Subfamily B, Member 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Base Pair Mismatch", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Transport", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calcium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclosporine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA-Binding Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Multiple", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Flow Cytometry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluoresceins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorescent Dyes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genes, MDR", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "K562 Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multidrug Resistance-Associated Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "MutS Homolog 3 Protein", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "RNA, Messenger", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcription, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Cells, Cultured", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service d\u2019h\u00e9matologie clinique, professeur Zittoun, H\u00f4pital H\u00f4tel-Dieu, 1 place du Parvis Notre Dame, 75 181, Paris, Cedex 04, France", 
          "id": "http://www.grid.ac/institutes/grid.411394.a", 
          "name": [
            "Formation de Recherche Claude Bernard and Service d\u2019h\u00e9matologie, H\u00f4pital H\u00f4tel Dieu, EA1529, Universit\u00e9 Paris VI, Paris, France", 
            "Service d\u2019h\u00e9matologie clinique, professeur Zittoun, H\u00f4pital H\u00f4tel-Dieu, 1 place du Parvis Notre Dame, 75 181, Paris, Cedex 04, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Legrand", 
        "givenName": "Ollivier", 
        "id": "sg:person.0752753564.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752753564.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Formation de Recherche Claude Bernard and Service d\u2019h\u00e9matologie, H\u00f4pital H\u00f4tel Dieu, EA1529, Universit\u00e9 Paris VI, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.462844.8", 
          "name": [
            "Formation de Recherche Claude Bernard and Service d\u2019h\u00e9matologie, H\u00f4pital H\u00f4tel Dieu, EA1529, Universit\u00e9 Paris VI, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Simonin", 
        "givenName": "Ghislaine", 
        "id": "sg:person.0603732723.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603732723.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Formation de Recherche Claude Bernard and Service d\u2019h\u00e9matologie, H\u00f4pital H\u00f4tel Dieu, EA1529, Universit\u00e9 Paris VI, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.462844.8", 
          "name": [
            "Formation de Recherche Claude Bernard and Service d\u2019h\u00e9matologie, H\u00f4pital H\u00f4tel Dieu, EA1529, Universit\u00e9 Paris VI, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Perrot", 
        "givenName": "Jean-Yves", 
        "id": "sg:person.0632736606.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632736606.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Formation de Recherche Claude Bernard and Service d\u2019h\u00e9matologie, H\u00f4pital H\u00f4tel Dieu, EA1529, Universit\u00e9 Paris VI, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.462844.8", 
          "name": [
            "Formation de Recherche Claude Bernard and Service d\u2019h\u00e9matologie, H\u00f4pital H\u00f4tel Dieu, EA1529, Universit\u00e9 Paris VI, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zittoun", 
        "givenName": "Robert", 
        "id": "sg:person.0717353373.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717353373.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Formation de Recherche Claude Bernard and Service d\u2019h\u00e9matologie, H\u00f4pital H\u00f4tel Dieu, EA1529, Universit\u00e9 Paris VI, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.462844.8", 
          "name": [
            "Formation de Recherche Claude Bernard and Service d\u2019h\u00e9matologie, H\u00f4pital H\u00f4tel Dieu, EA1529, Universit\u00e9 Paris VI, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marie", 
        "givenName": "Jean-Pierre", 
        "id": "sg:person.01064502270.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064502270.46"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1999", 
    "datePublishedReg": "1999-01-01", 
    "description": "Thirteen cell lines with different levels of Pgp and MRP1 expression were used to assess the ability of calcein-AM uptake and calcein efflux to measure Pgp and MRP1 functions, respectively. There was a good correlation between MRP1 expression and the modulatory effect of probenecid (a specific modulator of MRP1) on the calcein efflux (r=0.91, p=0.0003) and between Pgp expression and the modulatory effect of CsA on calcein-AM uptake (r=0.96, p<0.0001). On light of the high correlations for both proteins, we tested calcein-AM uptake and efflux in fresh myeloid leukemic cells. In 53 AML patients, there was also a good correlation between MRP1 expression (measured by RT/PCR and by MRPm6 expression by flow cytometry) and the modulatory effect of probenecid on the calcein fluorescence (r=0.92, p<0.0001) and between Pgp expression as measured by UIC2 antibody binding on flow cytometry and the modulatory effect of CsA on calcein-AM uptake (r=0.83, p<0.0001). Pgp activity was higher in CD34+ leukemia than in CD34- leukemia (2.26\u00b11.50 vs 1.46\u00b11.21 respectively, p=0.003) and MRP1 activity was higher in CD34- leukemia than in CD34+ leukemia (1.77\u00b10.40 vs 1.4\u00b10.29 respectively, p=0.004). Pgp expression and activity (p=0.004 and p=0.01, respectively), MRP1 activity (p=0.03) but not MRP1 expression were prognostic factors for achievement of CR. The effect of probenecid and CsA together were higher than the effect of either probenecid or CsA alone on calcein-AM uptake. These results suggest that functional testing (with calcein-AM\u00b1modulators) for the presence of both MRP1 and Pgp activities is of prognostic value and that MRP1 contributes to drug resistance in AML.", 
    "editor": [
      {
        "familyName": "Kaspers", 
        "givenName": "G. J. L.", 
        "type": "Person"
      }, 
      {
        "familyName": "Pieters", 
        "givenName": "R.", 
        "type": "Person"
      }, 
      {
        "familyName": "Veerman", 
        "givenName": "A. J. P.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4615-4811-9_18", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4613-7180-9", 
        "978-1-4615-4811-9"
      ], 
      "name": "Drug Resistance in Leukemia and Lymphoma III", 
      "type": "Book"
    }, 
    "keywords": [
      "calcein-AM uptake", 
      "MRP1 expression", 
      "modulatory effects", 
      "Pgp expression", 
      "MRP1 activity", 
      "CD34- leukemia", 
      "fresh myeloid leukemic cells", 
      "drug resistance", 
      "achievement of CR", 
      "calcein efflux", 
      "effect of probenecid", 
      "myeloid leukemic cells", 
      "prognostic factors", 
      "AML patients", 
      "prognostic value", 
      "Pgp activity", 
      "leukemic cells", 
      "flow cytometry", 
      "UIC2 antibody", 
      "MRP1 function", 
      "CsA", 
      "cell lines", 
      "AML", 
      "leukemia", 
      "probenecid", 
      "Pgp", 
      "CD34", 
      "efflux", 
      "MRP1", 
      "calcein fluorescence", 
      "expression", 
      "good correlation", 
      "uptake", 
      "functional testing", 
      "patients", 
      "activity", 
      "antibodies", 
      "cytometry", 
      "effect", 
      "correlation", 
      "high correlation", 
      "cells", 
      "resistance", 
      "contributes", 
      "levels", 
      "factors", 
      "testing", 
      "protein", 
      "different levels", 
      "presence", 
      "function", 
      "ability", 
      "lines", 
      "results", 
      "values", 
      "fluorescence", 
      "light", 
      "Cr", 
      "achievement"
    ], 
    "name": "Both Pgp and MRP1 Activities Using Calcein-AM Contribute to Drug Resistance in AML", 
    "pagination": "161-175", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034938308"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4615-4811-9_18"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10500791"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4615-4811-9_18", 
      "https://app.dimensions.ai/details/publication/pub.1034938308"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-06-01T22:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/chapter/chapter_452.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4615-4811-9_18"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4615-4811-9_18'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4615-4811-9_18'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4615-4811-9_18'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4615-4811-9_18'


 

This table displays all metadata directly associated to this object as RDF triples.

253 TRIPLES      23 PREDICATES      108 URIs      101 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4615-4811-9_18 schema:about N0090953e005a402c9c0b1c2be95d1c10
2 N0601e5e7ecea4acdb958bc1bc570c272
3 N2085d0a1a13c4fb4b0184c9d9dbcd7e7
4 N3f050b2bdfd746d8983c7dd63c633a00
5 N47f3e4c8b1a541b4b0fa42265ef6eea5
6 N49ab1124e3e445cb9d6fa8de4b85857d
7 N4daf341e7d6b4f8a9aebe6d9e43cdf37
8 N54127823d3394c8388e5db78829f28c2
9 N70941616af2e4911886ebd61c58c0ced
10 N74863b736ab44b9e84a55462087fd385
11 N765d3395135443579b93418f3dd73b6a
12 N9f65b8947a3b4402bb25b0c6e0ce6e32
13 Nb3170bbc52b74a47ba5b89936d7acd38
14 Nb5ce9ad63f4443b1908eacf9d7f954e3
15 Nbdb6239919474e69a470890f2fb772aa
16 Nc3c7ae2707834828a43601abed90c270
17 Ncdd43f81a8314fbb8580e1791ad3a75f
18 Nd5803e332c0847e2b0997a333a375288
19 Nea870784986043c7bd2cb8d1461ea709
20 Nf5d94085ef3b4daeaaf0b63512e0c4cd
21 Nf6e28ebd67ed4e93b5462e3072d9a1de
22 Nf83b382e745549a996f05fa613e9e2af
23 anzsrc-for:11
24 anzsrc-for:1112
25 schema:author Ncb07599238e147d69e1e7baa90330c7e
26 schema:datePublished 1999
27 schema:datePublishedReg 1999-01-01
28 schema:description Thirteen cell lines with different levels of Pgp and MRP1 expression were used to assess the ability of calcein-AM uptake and calcein efflux to measure Pgp and MRP1 functions, respectively. There was a good correlation between MRP1 expression and the modulatory effect of probenecid (a specific modulator of MRP1) on the calcein efflux (r=0.91, p=0.0003) and between Pgp expression and the modulatory effect of CsA on calcein-AM uptake (r=0.96, p<0.0001). On light of the high correlations for both proteins, we tested calcein-AM uptake and efflux in fresh myeloid leukemic cells. In 53 AML patients, there was also a good correlation between MRP1 expression (measured by RT/PCR and by MRPm6 expression by flow cytometry) and the modulatory effect of probenecid on the calcein fluorescence (r=0.92, p<0.0001) and between Pgp expression as measured by UIC2 antibody binding on flow cytometry and the modulatory effect of CsA on calcein-AM uptake (r=0.83, p<0.0001). Pgp activity was higher in CD34+ leukemia than in CD34- leukemia (2.26±1.50 vs 1.46±1.21 respectively, p=0.003) and MRP1 activity was higher in CD34- leukemia than in CD34+ leukemia (1.77±0.40 vs 1.4±0.29 respectively, p=0.004). Pgp expression and activity (p=0.004 and p=0.01, respectively), MRP1 activity (p=0.03) but not MRP1 expression were prognostic factors for achievement of CR. The effect of probenecid and CsA together were higher than the effect of either probenecid or CsA alone on calcein-AM uptake. These results suggest that functional testing (with calcein-AM±modulators) for the presence of both MRP1 and Pgp activities is of prognostic value and that MRP1 contributes to drug resistance in AML.
29 schema:editor N3f331a62ffff4b0cb0dec164df90c1cd
30 schema:genre chapter
31 schema:inLanguage en
32 schema:isAccessibleForFree false
33 schema:isPartOf Nbbfc6e6577254f56800bfd79ecdf459b
34 schema:keywords AML
35 AML patients
36 CD34
37 CD34- leukemia
38 Cr
39 CsA
40 MRP1
41 MRP1 activity
42 MRP1 expression
43 MRP1 function
44 Pgp
45 Pgp activity
46 Pgp expression
47 UIC2 antibody
48 ability
49 achievement
50 achievement of CR
51 activity
52 antibodies
53 calcein efflux
54 calcein fluorescence
55 calcein-AM uptake
56 cell lines
57 cells
58 contributes
59 correlation
60 cytometry
61 different levels
62 drug resistance
63 effect
64 effect of probenecid
65 efflux
66 expression
67 factors
68 flow cytometry
69 fluorescence
70 fresh myeloid leukemic cells
71 function
72 functional testing
73 good correlation
74 high correlation
75 leukemia
76 leukemic cells
77 levels
78 light
79 lines
80 modulatory effects
81 myeloid leukemic cells
82 patients
83 presence
84 probenecid
85 prognostic factors
86 prognostic value
87 protein
88 resistance
89 results
90 testing
91 uptake
92 values
93 schema:name Both Pgp and MRP1 Activities Using Calcein-AM Contribute to Drug Resistance in AML
94 schema:pagination 161-175
95 schema:productId N882dfd28e2224bc7ba6d599fd8b39c01
96 Nfa54cd0be7a54dc7b39047f29f3d29be
97 Nfb853818140f4f9a8c9e5d8e61f0d740
98 schema:publisher N02888e5962e4448a9d8e07900dcba1bf
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034938308
100 https://doi.org/10.1007/978-1-4615-4811-9_18
101 schema:sdDatePublished 2022-06-01T22:35
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher N0eaa46ad32494b849d07a0c62121e1f3
104 schema:url https://doi.org/10.1007/978-1-4615-4811-9_18
105 sgo:license sg:explorer/license/
106 sgo:sdDataset chapters
107 rdf:type schema:Chapter
108 N00453f7ef2c044f9a2bff84582bf68fa rdf:first sg:person.0603732723.41
109 rdf:rest N416ee60048f44730bf8477e3d95e99a3
110 N0090953e005a402c9c0b1c2be95d1c10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Transcription, Genetic
112 rdf:type schema:DefinedTerm
113 N02888e5962e4448a9d8e07900dcba1bf schema:name Springer Nature
114 rdf:type schema:Organisation
115 N0601e5e7ecea4acdb958bc1bc570c272 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Multidrug Resistance-Associated Proteins
117 rdf:type schema:DefinedTerm
118 N0a3d91172f1f406d8cb992b90b19d03f rdf:first sg:person.01064502270.46
119 rdf:rest rdf:nil
120 N0eaa46ad32494b849d07a0c62121e1f3 schema:name Springer Nature - SN SciGraph project
121 rdf:type schema:Organization
122 N2085d0a1a13c4fb4b0184c9d9dbcd7e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name MutS Homolog 3 Protein
124 rdf:type schema:DefinedTerm
125 N38f7ce22393448c4b03cfb1dbc5225bb schema:familyName Kaspers
126 schema:givenName G. J. L.
127 rdf:type schema:Person
128 N3f050b2bdfd746d8983c7dd63c633a00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Leukemia, Myeloid, Acute
130 rdf:type schema:DefinedTerm
131 N3f331a62ffff4b0cb0dec164df90c1cd rdf:first N38f7ce22393448c4b03cfb1dbc5225bb
132 rdf:rest N44cd23289a8d45bea2f3392c73603af4
133 N416ee60048f44730bf8477e3d95e99a3 rdf:first sg:person.0632736606.03
134 rdf:rest Ndf0db9fcb73a4ab69c17334fa07b8b9f
135 N44cd23289a8d45bea2f3392c73603af4 rdf:first Na808fc64acd9462c941e1551eb52fbbb
136 rdf:rest N5eb9e496f75144e9a43952aa8575e38e
137 N47f3e4c8b1a541b4b0fa42265ef6eea5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name RNA, Messenger
139 rdf:type schema:DefinedTerm
140 N49ab1124e3e445cb9d6fa8de4b85857d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Female
142 rdf:type schema:DefinedTerm
143 N4daf341e7d6b4f8a9aebe6d9e43cdf37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Drug Resistance, Multiple
145 rdf:type schema:DefinedTerm
146 N54127823d3394c8388e5db78829f28c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name ATP Binding Cassette Transporter, Subfamily B, Member 1
148 rdf:type schema:DefinedTerm
149 N5eb9e496f75144e9a43952aa8575e38e rdf:first Nd47d0a4eaa364d6ea5005c7795bdc5dd
150 rdf:rest rdf:nil
151 N70941616af2e4911886ebd61c58c0ced schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name K562 Cells
153 rdf:type schema:DefinedTerm
154 N74863b736ab44b9e84a55462087fd385 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Fluoresceins
156 rdf:type schema:DefinedTerm
157 N765d3395135443579b93418f3dd73b6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Humans
159 rdf:type schema:DefinedTerm
160 N882dfd28e2224bc7ba6d599fd8b39c01 schema:name pubmed_id
161 schema:value 10500791
162 rdf:type schema:PropertyValue
163 N9f65b8947a3b4402bb25b0c6e0ce6e32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Tumor Cells, Cultured
165 rdf:type schema:DefinedTerm
166 Na808fc64acd9462c941e1551eb52fbbb schema:familyName Pieters
167 schema:givenName R.
168 rdf:type schema:Person
169 Nb3170bbc52b74a47ba5b89936d7acd38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Biological Transport
171 rdf:type schema:DefinedTerm
172 Nb5ce9ad63f4443b1908eacf9d7f954e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Cyclosporine
174 rdf:type schema:DefinedTerm
175 Nbbfc6e6577254f56800bfd79ecdf459b schema:isbn 978-1-4613-7180-9
176 978-1-4615-4811-9
177 schema:name Drug Resistance in Leukemia and Lymphoma III
178 rdf:type schema:Book
179 Nbdb6239919474e69a470890f2fb772aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Fluorescent Dyes
181 rdf:type schema:DefinedTerm
182 Nc3c7ae2707834828a43601abed90c270 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name DNA-Binding Proteins
184 rdf:type schema:DefinedTerm
185 Ncb07599238e147d69e1e7baa90330c7e rdf:first sg:person.0752753564.08
186 rdf:rest N00453f7ef2c044f9a2bff84582bf68fa
187 Ncdd43f81a8314fbb8580e1791ad3a75f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Flow Cytometry
189 rdf:type schema:DefinedTerm
190 Nd47d0a4eaa364d6ea5005c7795bdc5dd schema:familyName Veerman
191 schema:givenName A. J. P.
192 rdf:type schema:Person
193 Nd5803e332c0847e2b0997a333a375288 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Base Pair Mismatch
195 rdf:type schema:DefinedTerm
196 Ndf0db9fcb73a4ab69c17334fa07b8b9f rdf:first sg:person.0717353373.00
197 rdf:rest N0a3d91172f1f406d8cb992b90b19d03f
198 Nea870784986043c7bd2cb8d1461ea709 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Male
200 rdf:type schema:DefinedTerm
201 Nf5d94085ef3b4daeaaf0b63512e0c4cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Genes, MDR
203 rdf:type schema:DefinedTerm
204 Nf6e28ebd67ed4e93b5462e3072d9a1de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Calcium
206 rdf:type schema:DefinedTerm
207 Nf83b382e745549a996f05fa613e9e2af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Antineoplastic Agents
209 rdf:type schema:DefinedTerm
210 Nfa54cd0be7a54dc7b39047f29f3d29be schema:name dimensions_id
211 schema:value pub.1034938308
212 rdf:type schema:PropertyValue
213 Nfb853818140f4f9a8c9e5d8e61f0d740 schema:name doi
214 schema:value 10.1007/978-1-4615-4811-9_18
215 rdf:type schema:PropertyValue
216 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
217 schema:name Medical and Health Sciences
218 rdf:type schema:DefinedTerm
219 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
220 schema:name Oncology and Carcinogenesis
221 rdf:type schema:DefinedTerm
222 sg:person.01064502270.46 schema:affiliation grid-institutes:grid.462844.8
223 schema:familyName Marie
224 schema:givenName Jean-Pierre
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064502270.46
226 rdf:type schema:Person
227 sg:person.0603732723.41 schema:affiliation grid-institutes:grid.462844.8
228 schema:familyName Simonin
229 schema:givenName Ghislaine
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603732723.41
231 rdf:type schema:Person
232 sg:person.0632736606.03 schema:affiliation grid-institutes:grid.462844.8
233 schema:familyName Perrot
234 schema:givenName Jean-Yves
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632736606.03
236 rdf:type schema:Person
237 sg:person.0717353373.00 schema:affiliation grid-institutes:grid.462844.8
238 schema:familyName Zittoun
239 schema:givenName Robert
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717353373.00
241 rdf:type schema:Person
242 sg:person.0752753564.08 schema:affiliation grid-institutes:grid.411394.a
243 schema:familyName Legrand
244 schema:givenName Ollivier
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752753564.08
246 rdf:type schema:Person
247 grid-institutes:grid.411394.a schema:alternateName Service d’hématologie clinique, professeur Zittoun, Hôpital Hôtel-Dieu, 1 place du Parvis Notre Dame, 75 181, Paris, Cedex 04, France
248 schema:name Formation de Recherche Claude Bernard and Service d’hématologie, Hôpital Hôtel Dieu, EA1529, Université Paris VI, Paris, France
249 Service d’hématologie clinique, professeur Zittoun, Hôpital Hôtel-Dieu, 1 place du Parvis Notre Dame, 75 181, Paris, Cedex 04, France
250 rdf:type schema:Organization
251 grid-institutes:grid.462844.8 schema:alternateName Formation de Recherche Claude Bernard and Service d’hématologie, Hôpital Hôtel Dieu, EA1529, Université Paris VI, Paris, France
252 schema:name Formation de Recherche Claude Bernard and Service d’hématologie, Hôpital Hôtel Dieu, EA1529, Université Paris VI, Paris, France
253 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...